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S U M M A R Y
Objective: Anterior thalamus (AN) has been shown to mediate seizures in both focal and generalized
models. Speciﬁc regional increase in AN serotonergic activity was observed following AN-DBS in our
pentylenetetrazol (PTZ) rodent model of acute seizures, and this increase may inhibit seizures and
contribute to the mechanism of anticonvulsant DBS.
Methods: Anesthetized rats with AN-directed dialysis cannula with scalp/depth EEG were infused with
PTZ at 5.5 mg/(kg min) until an EEG seizure occurred. Eight experimental groups of AN-dialysis infusion
were evaluated: controls (dialysate-only), 10 and 100 mM serotonin 5-HT7 agonist 5-carboxamido-
tryptamine (5-CT), 1, 10 and 100 mM serotonin antagonist methysergide (METH), AN-DBS, and 100 mM
METH + AN-DBS.
Results: Latency for seizures in control animals was 3120  770 s (S.D.); AN-DBS delayed onset to
5018  1100 (p < 0.01). AN-directed 5-CT increased latency in dose-dependent fashion: 3890  430 and
4247  528 (p < 0.05). Methysergide had an unexpected protective effect at low-dose (3908  550, p < 0.05)
but not at 100 mM (2687  1079). The anticonvulsant action of AN-DBS was blocked by prior dialysis using
100 mM METH. Surface EEG burst count and nonlinear analysis (H-Statistic) noted signiﬁcant (p < 0.05)
increased pre-ictal epileptiform bursts in 5-CT, methysergide, but not DBS group compared to control.
Conclusion: Increased serotonergic activity in AN raised PTZ seizure threshold, similar to DBS, but
without preventing cortical bursting. 5-Carboxamidotryptamine, a 5-HT7 agonist, demonstrated dose-
dependent seizure inhibition. Methysergide proved to have an inverse, dose-dependent agonist property,
antagonizing the action of AN-DBS at the highest dose. Anticonvulsant AN-DBS may in part act to
selectively alter serotonin neurotransmission to raise seizure threshold.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Our laboratory has in the past identiﬁed a unique cortical–
subcortical pathway from mesencephalic brainstem to anterior
thalamus (AN) with subsequent connections to cortex which is
important in the expression of acute seizures using the chemical
model pentylenetetrazol (PTZ).1–7 We have successfully observed
the efﬁcacy of focal deep brain stimulation (DBS) in the thalamic
region of this pathway as a means to raise seizure threshold.5,8–10
Recent evidence suggests that AN may also mediate pilocarpine-
induced seizures.11 Although PTZ is a model of seizures, and not* Corresponding author at: Division of Neurosciences Critical Care, Johns Hopkins
Hospital, 600 North Wolfe Street, Meyer 8-140, Baltimore, MD, 21287, USA.
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1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.06.011epilepsy, these data have propelled a clinical pilot trial of AN-DBS
in refractory human epilepsy.12–15 The results of this uncontrolled
pilot human data of 20 patients in four North American medical
centers has led to a Phase III industry-sponsored trial for refractory
partial epilepsy (SANTE).16,17
Recently, we published data demonstrating that focal AN-
serotonergic transmission may in part underscore the antic-
onvulsant action of site-speciﬁc AN-DBS.18 Site and transmitter
speciﬁc elevations in the serotonin metabolite 5-HIAA were
observed to rise in AN microdialysis samples during both the
expression of PTZ-induced acute seizures in rodents, and even
more so during anticonvulsant AN-DBS, suggesting a potential
link between the efﬁcacy of DBS and serotonergic transmission.
We therefore pursued electroencephalographic (EEG) evaluation
of the effects of microdialysis application of serotonin
agonist and antagonist compounds in the region of AN on PTZ
seizures.vier Ltd. All rights reserved.
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2.1. Animal preparation
All animal studies were conducted in accordance to the Johns
Hopkins Institutional Animal Care and Use Committee Guidelines.
Adult male Wistar rats (200–300 g; n = 42), anesthetized with
halothane/O2 (1.0–2.0%) were placed in a Kopf stereotactic frame.
Using aseptic surgical techniques and 1% lidocaine, the cranium
was exposed and a dental drill (Foredom, Bethel, CT, USA)was used
to expose the dura at coordinates derived from a stereotactic
atlas19 for bilateral placement of bipolar stimulating steel
electrodes (30 kV, 125 mm diameter with 250mm separation of
50 mm exposed tips) in the regions of AN (coordinates: 2.0 mm
anteroposterior from bregma, 1.5 mm lateral to the sagittal suture
and 5.5 mm deep from the dural edge). Depth electrode placement
was followed by introduction of dialysis probe-guide cannulas in
AN, and placement of four epidural EEG screw electrodes (Plastics
One, Roanoke, VA, USA). Dialysis probes used in these studies with
an effective dialysis membrane length of 3 mm (cut-off 6 Da, outer
diameter 0.24 mm) were obtained from CMA/microdialysis
(Chelmsford, MA, USA). The components were afﬁxed as a
headpiece with dental cement (Durelon, Espe, St. Paul, MN,
USA). The anesthetic was discontinued and the animals were
allowed to emerge from anesthesia in separate cages at room
temperature.
Following a 48 h recovery period with ad libitum access to food
and water, animals were reanesthetized with halothane (1.5%)/
oxygen for less than 15 min to allow placement of cannulas into
the right femoral artery and vein to monitor arterial blood
pressure, arterial blood gases and for drug infusion. Thereafter, the
animals were maintained at 0.5% halothane in the chamber. An
approximate 85% survival rate was achieved to this point.
Physiological levels of arterial blood gases were maintained
throughout the experiments; rectal temperature was maintained
at 37  0.5 8C with a heating lamp throughout surgical procedures
and the entire experimental protocol.
2.2. Serotonergic drug preparation and infusion
AN has a high population of serotonin 5-HT7 receptors
20;
therefore we selected the relatively speciﬁc 5-HT7 agonist 5-
carboxamidotryptamine (5-CT, Sigma–Aldrich, St. Louis, MO, USA).
Methysergide (METH, Sigma–Aldrich, St. Louis, MO, USA), a well-
described non-selective serotonin antagonist,21,22 was used to
discern inhibition at the serotonin receptor.Microdialysis cannulas
were perfused with artiﬁcial CSF (aCSF), alone at 1mL/min, or with
dissolved 5-CT or METH at appropriate concentration. The mmol/L
concentration of aCSF was as follows: NaCl 131.8, NaHCO3 24.6,
CaCl2 2.0, KCl 3.0, MgCl2 0.65, urea 6.7, and dextrose 3.7 in HPLC
grade water. The aCSF was ﬁltered, warmed to 378 C, and bubbled
with 95% N2/5% CO2 until pH, O2 and CO2 tensions were similar to
those of CSF and brain tissue.21.
In consecutive fashion, rats were prepared as above and
divided into eight treatment groups (each 6 animals each).
Control–surgical sham with no stimulation or dialysis drug
infusion; 10 mM and 100 mM 5-CT; 1 mM, 10 mM, and 100 mM
METH; AN-DBS with 100 mM METH dialysis; and AN-DBS with
saline AN infusion. The combination of bipolar stimulating
electrode with dialysis cannula was performed with the cannula
tip 1 mm dorsal to the tip of the adhered stimulating electrode.
Such a construct reduced co-axial damage while permitting
gravity supported diffusion. PTZ (20 mg/ml in saline, Sigma–
Aldrich, St. Louis, MO, USA) was infused (T0) beginning 20 min
following initiation of dialysate infusion (T0–20) at a rate of5.5 mg/(kg min) via a syringe infusion pump (Harvard Instru-
ments, Holliston, MA, USA), a rate of infusion that reliably
induced seizures within 50–60 min in control animals. Follow-
ing completion of experiments, animals received a lethal
injection of pentobarbital and brains were perfusion-ﬁxed with
buffered 3% formalin, and brains cut for localization of electrode
tips. Animals designated as AN-hit had the electrode tips in, or
within 1 mm of AN.
2.3. AN stimulation
Bilateral AN-DBSwas delivered using a Grass Constant Current
stimulator (West Warwick, RI, USA): 100 Hz; 150 mA; 0.1 ms
pulse duration beginning 40 min prior to PTZ infusion (T0–40) and
continuing during the infusion of the convulsant until the
elicitation of the ﬁrst severe generalized EEG seizure lasting
>10 s. Stimulation current wasmeasured by connecting the input
leads from a Tektronix 5103A dual beam oscilloscope (Beaverton,
OR, USA) across a 1 kV resistance in series with one of the
stimulus output leads. The stimulation frequency of 100 Hz was
selected based on our previously reported data using high
frequency rate of stimulation in the anterior thalamus.5 Continual
cortical and AN EEGs were recorded using a Grass Instruments
Model 79D eight-channel EEG unit. The ﬁlter settings on the EEG
were 0.3 Hz (high pass ﬁlter) 300 Hz (low pass ﬁlter). The
sampling rate was 1000 Hz. The epidural EEG recording was
four-channel: frontal, posterior, left, right bipolar montage with
electrode placement 1 cm on each side of sagittal suture, 1 cm
anterior and posterior to bregma. Depth electrodes recorded
regional ﬁeld activity from AN.
2.4. EEG signal analysis
Seizures were deﬁned by 10 s of rapid high voltage (>100 mV)
hypersynchronous discharge (RHD). Additional paroxysms
observed were a mixture of single spike (0–70 ms) or sharp
(70–200 ms) activity, polysharp-polyspike, and crescendo-decres-
cendo 0.5–2.0 s, 50–100mV transient bursts. All were easily
discernible from background EEG. During AN-DBS trials, the
ampliﬁers at the recording site were shut off during stimulation,
and 10–15 s was allowed for dissipation of currents when
switching on ampliﬁer circuit for periodic EEG recording. EEGs
from all animals were quantitatively reviewed both visually and
using an H-Statistic seizure detection method.24
Post hoc quantiﬁcation of sharp/spike count pre-ictally was
performed on the 5-CT andMETH infusion groups via twomethods
by an investigator blinded to the pharmacological or DBS stimulus
effects. The ﬁrst was by visual quantiﬁcation of paroxysms on the
digital EEG. The second was by analyzing the EEG using the H-
Statistic, a nonlinear-based method which has been shown to
outperform traditional spike detection methods that examine 2nd
order autocorrelations out of a matched autoregressive modeled
system.25,26 The test is particularly useful in detecting nonlinear
dependencies, which we have shown is characteristic of burst
episodes in the recovering EEG.27,28
2.5. Statistical analysis
Statistical analysis was performed using multiple analysis of
variance (MANOVA using both Bonferroni and Scheffe’s post hoc
corrections) and Student’s t-test. Statistical software was SPSS
for Windows (Version 11.0.1. 2001. Chicago: SPSS Inc.). Alpha
values were set at 0.05 (two-tailed), the zero-sensitivity was
therefore 0.95 for each comparison. Data are presented as
mean  S.D.
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Animals in all groups completing the experimental protocol
were maintained in a stable physiological state, with an expected
shift from an alkalotic to mildly acidotic state between pre-ictal to
post-ictal states (pH 7.44–7.32).
3.1. Histology
Post hoc review conﬁrmed an 81% (48/59) success rate of AN
electrode/cannula insertion. Animals with electrodes or cannula in
alternative locations were analyzed as a group under Section 3.2.6
(see below).
3.2. Seizure threshold
3.2.1. Controls
In control, aCSF-infused AN animals, PTZ infusion resulted
in stereotypic progression of cortical EEG stimulation, progres-
sing to a generalized seizure associated with RHD EEG
discharges recorded both from AN and surface electrodes
(Fig. 1). The mean onset time of the seizure was 3,120  770 s
(Fig. 2).
3.2.2. AN-DBS
Compared to sham control animals, bilateral AN stimulation
resulted in a highly signiﬁcant increase in threshold to the ﬁrst
generalized severe seizure which occurred at 5018  1078 s after
start of PTZ infusion (286 mg/kg total PTZ dose in controls vs. 460 mg/
kg) (p < 0.01).
3.2.3. 5-CT
AN infusion of the serotonin 5-HT7 agonist resulted in a dose-
dependent delay in PTZ seizure threshold. At 10 mM, 5-CT infusion
delayed seizure threshold by 25% to 3890  430 s (p < 0.05), and at
100 mM infusion, the threshold was increased by 36% to 4247  528
(p < 0.02) (Fig. 2).Fig. 1.Representative cortical and subcortical EEG during constant intravenous infusion o
onset of generalized EEG seizure throughout all leads. Abbreviations: AN, anterior thala3.2.4. Methysergide
Infusion ofMETH resulted in a dose-dependent response on PTZ
seizure threshold. At 1mMdialysate concentration,METH elevated
seizure threshold to 3,908  550, a delay by 25%. At 10 mM, PTZ
seizures were delayed only to 3731  1345, a < 20% increase in
threshold. The downward trend prompted evaluation of 100 mM,
which further lowered seizure threshold to 2687  1079, statistically
signiﬁcant from controls (p < 0.05) (Fig. 2).
3.2.5. Methysergide + AN-DBS
Infusion of 100 mMMETH eliminated the anticonvulsant effect
of AN-DBS. The mean seizure latency of the group was virtually
identical (3298  1276 s) to 100 mM METH alone (3298  1276)
(Fig. 2).
3.2.6. Missed AN
Of the 12 animals with cannula or electrodes outside the
deﬁned boundaries of AN, two received stimulating electrode
implants (AN-DBS) and the other 10 were implanted with infusion
cannula for 5-CT (n = 5), methysergide (2), or both cannula and
stimulating electrodes (3). Localization included striatum (4),
medial dorsal nucleus (3), and ventral or posterior thalamic regions
(5). All ‘‘AN misses’’ manifested electrographic seizure threshold
similar to control animals, between 3075 and 3480 s.
3.3. Electroencephalographic changes
3.3.1. Direct quantitative
In controls, early, intermittent 1 s medium voltage sharp-wave
bursts were observed 5–10 min following initiation of the con-
vulsant infusion, followed by single high voltage (>150–250mV)
spike or multiple spike and sharp-wave complexes each lasting less
than 1–2 s at 4–8 Hz (Fig. 3). AN-DBS paralleled the pre-ictal activity
observed in control animals. Only beyond the PTZ control seizure
threshold did the frequency of paroxysmal elements increase in this
group of animals until seizure threshold was attained. In the
serotonergic infusion studies, peri-ictal paroxysmal EEG activitywasf the chemical convulsant pentylenetetrazol (PTZ) in sedated animals demonstrating
mus.
Fig. 2. Comparative seizure threshold latency to pentylenetetrazol (PTZ) between control animals (PTZ-alone) and animals treatedwith PTZ and AN-DBS, serotonin agonist 5-
carboxamidotryptamine (5-CT), the antagonist methysergide, or methysergide + DBS. Note signiﬁcant increase in latency in response to DBS and dose-dependent increasing
dose of 5-CT, and the protective effect of low-dose methysergide that is lost at higher doses  S.D., **p < 0.02 between control (PTZ-alone) vs. either 100 mM 5-CT or AN-DBS
stimulation. *p < 0.05 control vs. 10 mM 5-CT or 1 mM methysergide, §p < 0.05 between AN-DBS and 100 mM methysergide and 100 mM methysergide + AN-DBS. Abbreviations:
DBS, deep brain stimulation.
Fig. 3. Visual quantiﬁcation of pre-ictal epileptiform EEG burst activity during systemic PTZ infusion. (A) Comparison between control, AN-DBS, and the serotonin agonist 5-
CT at 10mM and 100 mMAN-dialysate concentration; (B) comparison between control, AN-DBS, and the serotonin antagonist methysergide at 10 and 100 mMAN-dialysate
concentration. The termination of each line represents the seizure threshold for each animal group. In both comparisons, note rise in pre-ictal paroxysms in both the 5-CT and
methysergide groups as compared with AN-DBS  S.D., p < 0.05 between both concentrations of 5-CT and methysergide vs. control or AN-DBS (MANOVA). Abbreviations: PTZ,
pentylenetetrazol; AN, anterior thalamus; 5-CT, 5-carboxamidotryptamine; DBS, deep brain stimulation.
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Fig. 4. H-Statistic EEG signal quantiﬁcation of pre-ictal epileptiform EEG burst activity during systemic PTZ infusion. (A) Comparison between control, AN-DBS, and the
serotonin agonist 5-CT at 10 and 100 mMAN-dialysate concentration; (B) comparison between control, AN-DBS, and the serotonin antagonistmethysergide at 10 and 100 mM
AN-dialysate concentration. Note consistent, early rise in H-Statistic (pre-2000 s) in the 5-CT and methysergide groups as compared to visual inspection data in Fig. 3. S.D.,
p < 0.05 between both concentrations of 5-CT and methysergide vs. control or AN-DBS (MANOVA); p < 0.05 between H-Statistic and visual inspection in 5-CT and methysergide
groups. Abbreviations: PTZ, pentylenetetrazol; AN, anterior thalamus; 5-CT, 5-carboxamidotryptamine; DBS, deep brain stimulation.
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controls (p< 0.05), despite a robust anticonvulsant effect by 5-CT
and low-doseMETH in raising seizure threshold (Fig. 3). Even during
high-dose METH infusion that resulted in control level seizure
threshold, the pre-ictal spike and sharp-wave activity was much
greater than in the control population.
3.3.2. H-Statistic
The H-Statistic was employed to quantify all epileptiform
paroxysms, both subtle and overt. In comparison between visual
inspection and the H-Statistic in both the transmitters and DBS
interventions (Fig. 4), the latter was particularly more sensitive
earlier in the PTZ infusion (pre-2000 s), where subtle, yet
consistent epileptiform aberrations of the EEG failed to be
discriminated from background by simple visual inspection
(p < 0.05 between two methods).
4. Discussion
It was observed in previous experiments that anticonvulsant
stimulation speciﬁcally raised serotonergic turnover in AN as
compared to other thalamic transmitter systems, and suggested
that AN-DBSmay impart its anticonvulsant action against systemic
PTZ through alteration of AN serotonergic activity.18 The results
here clearly demonstrated that serotonergic agonist modulation
using 5-CT within AN did indeed raise seizure threshold in a dose-
dependent fashion. This anticonvulsant effect, using the higher of
the two doses (100mM), paralleled the elevation in seizurethreshold induced by focal AN-DBS. High-dose METH, in contrast,
antagonized the action of AN-DBS. In addition, blocking the
anticonvulsant effect of AN-DBS by the serotonin antagonist METH
supports the hypothesis that DBS may therapeutically act, in part,
via alteration of transmitter mediated synaptic function.
The implication that serotonergic transmission may play a key
role in seizure expression has also been well recognized for some
time,29–33 and demonstrated in both chemical seizure models as
well as genetic epilepsy-prone rodents (GEPR).34–37 It has been
hypothesized in GEPR rats, for example, that there is a deﬁcit of
regional brain serotonin that leads to seizure susceptibility,38,39
and such reasoning is supported by the efﬁcacy in treatment
observed with serotonin re-uptake inhibitors.37 Agents that
antagonize serotonin binding conversely have a tendency to act
as proconvulsants.35,37,39,40
What remains obscure is the precise relationship this trans-
mitter plays within pro- and anticonvulsant networks since
experimental studies are often contradictory. In our model, 5-
HT7 agonism by 5-CT raised seizure threshold to PTZ, but blocking
this receptor subtypewas protective in amouse audiogenic seizure
model.38 Such ambiguity may reside in evidence that points to
both somatodendritic as well as postsynaptic 5-HT receptors, thus
enabling a variety of facilitory and inhibitory actions in different
model systems.41,42 Evenwithin a given seizuremodel, differential
afﬁnities of 5-HT agonist and antagonist agents for pre- vs.
postsynaptic binding sites (such as the receptors 5-HT1B and 5-
HT1A, respectively) may lead to opposite actions regarding
proconvulsant tendencies.
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HT7 receptor, highly concentrated in AN in rodents.
20,22 METH is a
well described non-selective serotonin antagonist,21,23,42–44, and
has been reported to speciﬁcally exacerbate PTZ seizures in
mice.31 Nonetheless, in our seizure model, low-dose METH
increased seizure threshold, and only at higher doses was speciﬁc
antagonism of 5-CT observed. It is likely that the non-selective
property of METH underscores its variable action. Similar
observations were made by Holden et al. where METH inexplic-
ably proved no different from control in antagonizing serotonin 5-
HT1 and 5-HT3 receptor effects.
45 The authors suggested that the
broad action of METH against serotonin receptors may underlie
the poor response.
The mechanisms of DBS, whether for epilepsy or movement
disorders, also remain incompletely understood. There is some
evidence that stimulation may result in a predominant inhibitory
inﬂuence through membrane hyperpolarization.46 Using a ﬁnite
element model of a DBS electrode with the ﬁeld applied to a three-
dimensional multi-compartment neuron model, evidence sup-
ports that the stimulation effects were excitatory near the
electrode and that synaptic terminals and axons of passage had
lower thresholds and were excited over a greater volume of tissue
than local neuronal cell bodies.47,48 The synaptic terminal may also
be independently inﬂuenced by DBS. Such threshold data may
explain how output can be increased from a stimulated structure
even though local neuronal activity is inhibited.49,50 The presence
of dorsal raphe nucleus (DRN) to AN serotonergic pathways and 5-
HT1 heteroreceptors mapped to terminals of AN-derived thala-
mocortical projections51 supports the possibility of such seroto-
nergic seizure modulation within AN.
The greater anticonvulsant effect of AN DBS than dialyzed 5-
CT may reﬂect a more localized effect of electrical stimulation
compared to the diffusion effects of dialyzed serotonin agonists.
The current–distance curve presented by Ranck indicates that a
0.2 ms 150 mA pulse from a monopolar depth electrode
stimulates axons or cell bodies only up to 1.0 mm away.49 In
contrast, autoradiographic studies using dialysis probes similar
to ours demonstrated that label spread radially from the dialysis
probe with a maximum diameter of approximately 3 mm by 1 h
of perfusion.52 Alternatively, as electrical stimulation preferen-
tially activates ﬁbers of passage rather than neurons, the AN-
DBS may affect different neuronal networks that contribute to
the ﬁnal thalamocortical inﬂuence on the cortical EEG. Such
distinction between the effects of dialysis and DBS appears
corroborated by different actions on the pre-ictal cortical EEG.
As noted by the H-Statistic signal analysis, electrical stimulation
during the DBS pre-ictal period greatly reduced the seizure
paroxysms as compared to the pre-ictal period when 5-CT or
METH was administered. AN-DBS appeared to delay the seizure
while not altering the direct cortical action of PTZ, while both 5-
CT and METH gave rise to large incremental increases in the pre-
ictal H-Statistic.
How these data may translate to human epilepsy remains
conjectural. Although PTZ has been used for decades as an effective
screening tool for clinical anticonvulsants, the chemical is an
animalmodel of acute seizures, not epilepsy. Results of current AN-
DBS in human epilepsy studiesmay offer clinical correlation. These
current data do, however, support the premise that electrical
stimulation may act in part via modulating serotonergic activity.
Our results also distinguish between DBS and serotonin mechan-
isms in raising seizure threshold, as evidenced by distinct
inﬂuences on the pre-ictal cortical EEG. Further investigation
using selective 5-HT7 antagonists and with concurrent AN-DBS
would prove useful in further discriminating the anticonvulsant
actions of these two methods.Acknowledgements
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